Navigation Links
Pradaxa® (dabigatran etexilate mesylate) Capsules Now on Formulary at Nation's Top Heart Hospitals
Date:7/21/2011

logical bleeding and patients with a known serious hypersensitivity reaction (e.g., anaphylactic reaction or anaphylactic shock) to PRADAXA.

WARNINGS AND PRECAUTIONS

Risk of Bleeding

PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding.

Risk factors for bleeding include:

- Medications that increase the risk of bleeding in general (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs).

-Labor and delivery

Promptly evaluate any signs or symptoms of blood loss, such as a drop in hemoglobin and/or hematocrit or hypotension. Discontinue PRADAXA in patients with active pathological bleeding.

Temporary Discontinuation of PRADAXA

Discontinuing PRADAXA for active bleeding, elective surgery, or invasive procedures places patients at an increased risk of stroke.  Lapses in therapy should be avoided, and if PRADAXA must be temporarily discontinued for any reason, therapy should be restarted as soon as possible.

Effect of P-gp Inducers and Inhibitors on PRADAXA Exposure

The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces dabigatran exposure and should generally be avoided. P-gp inhibitors ketoconazole, verapamil, amiodarone, quinidine, and clarithromycin, do not require dose adjustments. These results should not be extrapolated to other P-gp inhibitors.

ADVERSE REACTIONS

In the pivotal trial comparing PRADAXA to warfarin, the most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal (GI) events. PRADAXA 150 mg resulted in a higher rate of major GI bleeds and any GI bleeds compared to warfarin. In patients greater than or equal to 75 years of age, the risk of major bleeding may be greater with PRADAXA than with warfarin. Patients on PRADAXA 150 mg had an increased incidence of GI adverse reactions.  These
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)
2. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
3. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
4. Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
5. Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
6. Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
7. FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
8. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
9. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
10. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
11. Roxane Laboratories, Inc. Announces the Launch of Mycophenolate Mofetil 250mg Capsules and 500mg Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
(Date:1/14/2014)... 2014 During the 1600’s through the 1800’s ... Doctor’s Plague.” In this time period, doctors did not know ... times, to the death of vulnerable patients. In the same ... they may be unwittingly transmitting herpes viruses to their patients. ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of Care ... novel disease specific POC tests, announced today that it has ... of $690,000. The investment is from private investors and is ... of private investors has significant successful experience in early investments ...
(Date:1/14/2014)... Translational Biosciences, a subsidiary of ... trial approval for the treatment of rheumatoid arthritis ... from the Comité Nacional de Bioética de la ... (RA) is an autoimmune disease in which the ...
Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
... ... Screening Capabilities Yield High-quality Data for the Broad Institute,s NIH-funded Molecular Libraries and Imaging ... Lexington, ... leading provider of in silico solutions for pharmaceutical R&D and related life sciences, today ...
... Oct. 5 Verenium Corporation (Nasdaq: VRNMD ), ... and high-performance specialty enzymes, today announced that it intends ... shares of its common stock, and potentially warrants, in ... to price before 9:30 am EDT on Tuesday, October ...
... UPPSALA, Sweden, October 5 , ... - At One Sixth the Price of QuanTyper(TM) Without Loss ... to Rapidly Penetrate the Market , AlphaHelix ... - AmpXpress(TM) - to meet demands for lower,instrument prices. This was ...
Cached Biology Technology:Genedata Screener Supports Small Molecule Research at the Broad Institute of Harvard and MIT 2Genedata Screener Supports Small Molecule Research at the Broad Institute of Harvard and MIT 3Genedata Screener Supports Small Molecule Research at the Broad Institute of Harvard and MIT 4Verenium Announces Proposed Public Offering of Common Stock 2Verenium Announces Proposed Public Offering of Common Stock 3AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show 2
(Date:4/18/2014)... Ill. For the past 20 years, researchers have ... the research findings have suggested that soil organic carbon ... conventional tillage systems to no-till systems. However, there is ... systems in corn and soybean rotations without cover crops, ... organic carbon stocks at the published rates. , "Some ...
(Date:4/18/2014)... Calif. A team of researchers led by ... been selected to receive a $7.5 million Department of ... simple and basic scientific foundations for the predictable design ... a wide diversity of structures from plants and animals, ... are taking what biological systems have constructed over millions ...
(Date:4/17/2014)... there was a word for chili peppers. Information about ... with a study of the appearance of words for ... where jalapeos were domesticated and highlight the value of ... Kraft et al.) of nine papers presented in a ... National Academy of Sciences on plant and animal ...
Breaking Biology News(10 mins):Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3Chickens to chili peppers 2Chickens to chili peppers 3
... on biodiversity pose a serious conservation challenge for marine life, ... may need to relocate faster than land species as well ... cycle events. This challenges previous thinking that marine life in ... because of slower warming in the oceans. "Analyses of ...
... University of Cambridge study, which set out to investigate DNA ... our lifestyle and our health, has now mapped the link ... data collected greatly benefits a field that is still in ... where the researchers were, even 18 months ago. ...
... from UCLA,s cancer and stem cell centers have demonstrated for ... to create cancer-killing T-cells that seek out and attack a ... in 40 percent of Caucasians with this malignancy. Done ... blood stem cells, which make every cell type found in ...
Cached Biology News:No plain sailing for marine life as climate warms 2No plain sailing for marine life as climate warms 3Environment and diet leave their prints on the heart 2UCLA researchers engineer blood stem cells to fight melanoma 2UCLA researchers engineer blood stem cells to fight melanoma 3
...
... supplies, for 10 chips, provides the ... standard-sensitivity RNA analysis (nanogram levels) with ... electrophoresis system. Supplied are 1,250 microliters ... stain, 20 microliters RNA ladder, 900 ...
MAb to Verotoxin II (SLT-2a) Verotoxin II (Shiga-like) A subunit (SLT-2a)...
...
Biology Products: